Genelux (NASDAQ:GNLX) Upgraded at Lucid Cap Mkts

Posted by on Sep 19th, 2026

Lucid Cap Mkts upgraded shares of Genelux (NASDAQ:GNLX – Free Report) to a strong-buy rating in a report published on Wednesday,Zacks reports.

Several other equities analysts have also recently issued reports on GNLX. Wall Street Zen upgraded shares of Genelux from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a research report on Friday, July 17th. Finally, Benchmark reiterated a “speculative buy” rating on shares of Genelux in a report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.00.

View Our Latest Stock Report on GNLX

Genelux Stock Performance

Shares of GNLX stock opened at $2.53 on Wednesday. Genelux has a fifty-two week low of $2.29 and a fifty-two week high of $8.53. The firm has a market cap of $114.46 million, a P/E ratio of -2.94 and a beta of 0.57. The business’s 50 day moving average price is $2.71 and its 200-day moving average price is $2.76.

Genelux (NASDAQ:GNLX – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). As a group, equities analysts predict that Genelux will post -0.81 EPS for the current year.

Insider Activity at Genelux

In other news, Director John W. Smither sold 12,000 shares of Genelux stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $2.91, for a total value of $34,920.00. Following the completion of the sale, the director directly owned 91,403 shares in the company, valued at $265,982.73. The trade was a 11.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Thomas Zindrick sold 34,463 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $2.67, for a total transaction of $92,016.21. Following the transaction, the chief executive officer owned 1,226,427 shares in the company, valued at approximately $3,274,560.09. This trade represents a 2.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 59,822 shares of company stock valued at $164,402. 7.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Genelux

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Genelux in the second quarter worth $1,323,000. Bank of America Corp DE bought a new position in Genelux in the second quarter valued at about $990,000. Flputnam Investment Management Co. purchased a new position in Genelux in the second quarter worth about $697,000. Global Retirement Partners LLC bought a new stake in shares of Genelux during the 2nd quarter valued at about $686,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Genelux during the 2nd quarter valued at about $257,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

About Genelux

(Get Free Report)

Genelux Corporation is a clinical-stage biotechnology company focused on developing and commercializing therapies for cancer. The company’s research centers on oncolytic immunotherapies, which are designed to selectively infect and destroy tumor cells while stimulating the body’s immune response against cancer.

Genelux’s lead investigational product is olvimulogene nanivacirepvec, also known as Olvi-Vec or GL-ONC1. Olvi-Vec is a modified vaccinia virus being evaluated in clinical studies for several solid tumors, including ovarian cancer and other advanced or recurrent cancers.

Featured Articles

Analyst Recommendations for Genelux (NASDAQ:GNLX)

Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.